Navigation Links
They are young and need the job: A second chance for dangerous T-cells
Date:6/15/2009

The immune system's T-cells react to foreign protein fragments and therefore are crucial to combating viruses and bacteria. Errant cells that attack the body's own material are in most cases driven to cell death. Some of these autoreactive T-cells, however, undergo a kind of reeducation to become "regulatory T-cells" that keep other autoreactive T-cells under control. A group led by immunologist Professor Ludger Klein of LMU Munich has now shown that the developmental stage of an autoreactive T-cell is decisive to its ultimate destiny. Young autoreactive T-cells are very readily reeducated into regulatory T-cells. Under identical conditions, however, older T-cells become fully activated and can cause damage they are in a way resistant to reeducation. "We now intend to study at the molecular level what makes a T-cell accessible for reeducation," said Klein, "because then it may be possible to convert even normal adult T-cells, which can be obtained easily and in great numbers from blood. Possibly, they could then be used as regulatory T-cells in therapies for autoimmune diseases such as type-1 diabetes or multiple sclerosis: these are diseases that are triggered by uncontrolled autoreactive T-cells." (PNAS, 10 June 2009)

During their development in the thymus gland, a kind of 'T-cell school', every T-cell is fitted out with its own personal receptor. The diversity of these receptors allows the immune system to respond to nearly all pathogens. Since T-cell receptors are all randomly constructed, there is also a constant production of T-cells in the thymus that may recognize and attack the body's own structures. "Most of these dangerous autoreactive T-cells, though, are sorted out in a screening process before they leave the thymus," Klein reported. "This negative selection, that is the elimination of autoreactive T-cells that would otherwise attack their own organism, is an important requirement for immune tolerance."

But not all autoreactive
'/>"/>

Contact: Dr. Ludger Klein
ludger.klein@med.uni-muenchen.de
49-089-218-075-696
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Promising device snags young inventors coveted spot at IShow
2. Five outstanding young gastroenterologists receive AGA Foundation 2009 Research Scholars Award
3. System that regulates blood pressure is amiss in some healthy, young blacks
4. 6 young ASU faculty earn NSF Career awards
5. ONR announces 2009 Young Investigator Award recipients
6. Oral contraceptives impair muscle gains in young women
7. Computational model examines the pathways of Alzheimers that strikes at the young
8. Oral contraceptives impair muscle gains in young women
9. Computational model examines the pathways of Alzheimers that strikes at the young
10. Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements
11. Young dinosaurs roamed together, died together
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... in Antarctica, funded by the National Science Foundation (NSF), have ... and greenhouse gases in the atmosphere that extends back 68,000 ... the ice containing the record is known as the WAIS ... the core contain uniquely detailed information on past environmental conditions ...
... molds and fungi, bacteria and viruses. To kill them off ... are, as a rule, treated chemically. However, recently this method ... have been withdrawn, but the granting of new permits has ... E. coli infection which was caused by beansprout ...
... ARBORMany medically minded researchers are in hot pursuit of ... and the interiors of cells, but University of Michigan ... to overcome: escaping the bloodstream. Drug delivery ... medicines could be more effective at lower doses and ...
Cached Biology News:Antarctic ice core contains unrivaled detail of past climate 2Antarctic ice core contains unrivaled detail of past climate 3Healthy seeds -- treated environmentally friendly 2Healthy seeds -- treated environmentally friendly 3Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 2Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 3
(Date:12/13/2014)... 2014 The “Global Synthetic Biology ... drivers, threats, opportunities, and challenges. , The global ... players, namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont ... jointly accounted for approximately ~65% of the total ... Copy for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html ...
(Date:12/13/2014)... York (PRWEB) December 13, 2014 QuickSTAT ... global network and Cold Chain capabilities, and is delighted ... in Paris, France, to serve Life Science clients in ... equipped with a controlled-ambient warehouse, will provide 24/7 transportation ... vaccines and investigational drugs, patient-clinical specimens, API, following IATA ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Glucose Sensors: the Next Generation" ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of ... giving hope for a better future to millions ... can measure glucose levels accurately and reliably have ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... the company has regained compliance with Marketplace Rule,4450(a)(5) (the ... bid,price of the Company,s common stock. Nasdaq had previously ... stock had failed to maintain a,minimum bid price of ...
... 29 /Xinhua-PRNewswire-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" ... Republic of China ("PRC"),today reported solid financial results for ... Fourth Quarter Fiscal 2007 Highlights, -- ... the fourth quarter of 2006, ...
... Verizon Keynote at Leading Pharmaceutical Communication Event, Where Executives Gather to ... for Pharmaceutical, Biotech and Medical Technology ... ... pleased to announce the participation of two keynote speakers from the,U.S. Food ...
Cached Biology Technology:Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 2Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 3Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 4Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 5Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 6Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 7Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 8Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 9FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 2FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 3
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Glutathione Agarose Beads 10 ml...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products: